Market Overview:
The global amyotrophic lateral sclerosis drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of ALS, rising awareness about ALS, and technological advancements in the field of ALS drugs. The global amyotrophic lateral sclerosis drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into riluzole, edaravone (Radicava), CoQ10, butylphthalide, and others. On the basis of application, the market is segmented into hospital pharmacies, retail pharmacies,, online pharmacies,. Geographically speaking,, North America dominates this market followed by Europe and Asia Pacific respectively. However,. Latin America,.
Product Definition:
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rare neurodegenerative disorder that affects nerve cells in the brain and spinal cord. ALS causes muscle weakness and atrophy throughout the body. As the disease progresses, patients lose the ability to speak, eat, move, and breathe. There is no cure for ALS and no effective treatments currently exist. However, medications may provide some relief from symptoms or improve quality of life for patients with ALS.
Riluzole:
Riluzole (Rilutek) is an anti-epileptic drug which is FDA approved for the treatment of both generalized and partial seizures. It was developed by Hoffmann-La Roche Ltd. in the 1970s as a replacement for phenobarbital, primidone, and carbamazepine in epilepsy treatment.
Edaravone (Radicava):
Edaravone (Radicava) is an oral drug used for the treatment of ALS, a progressive neurodegenerative disorder. The drug works by enhancing the survival of motor neurons and has shown promising results in clinical trials. It is currently under phase III clinical trial for ALS and phase II clinical trial for frontotemporal dementia.
Application Insights:
Based on application, the global amyotrophic lateral sclerosis drugs market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacy held the largest share of the application segment in 2017 owing to availability of a wide range of medicines in hospitals that are hard to get from other sources.
Retail pharmacy is expected to be fastest growing market for ALS drugs over forecast period due to increasing awareness about treatment among general population and high demand for these medicines at home as compared at hospitals or clinics where they are available only by prescription. Online pharmacies have been observed effective than their offline counterparts in providing convenience along with better accessibility and affordability that has contributed significantly towards growth over past few years.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing regional market with a CAGR of XX% over the forecast period. The presence of a large patient base and favorable reimbursement policies are some factors contributing to this growth. In addition, increasing awareness about amyotrophic lateral sclerosis and growing healthcare expenditure in developing countries such as India & China are anticipated to drive the market during the forecast period.
In 2016, Japan contributed approximately 30% of global riluzole sales owing to its aging population coupled with increased incidence rates of ALS which has prompted people affected by it or their families towards seeking treatment options for amyotrophic lateral sclerosis drugs in Japan thus driving growth over past few years (Figure 1). Increasing government initiatives being undertaken across various Asia Pacific countries for raising awareness about this disease is also expected fuel demand during forecast period (Figure 2).
Growth Factors:
- Increasing incidence of ALS
- Growing awareness about ALS and its treatment options
- Rising demand for better and more effective therapies for ALS
- Availability of government funding for research on ALS drugs
- Entry of new players in the market
Scope Of The Report
Report Attributes
Report Details
Report Title
Amyotrophic Lateral Sclerosis Drugs Market Research Report
By Type
Riluzole, Edaravone (Radicava), CoQ10, Butylphthalide, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Sanofi, Mitsubishi Tanabe Pharma, Mylan, Apotex, Glemark Generics, Sun Pharma, Covis Pharma, Lunan Pharma, CSPC Pharmaceutical, Ascend Laboratories, EISAI
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Amyotrophic Lateral Sclerosis Drugs Market Report Segments:
The global Amyotrophic Lateral Sclerosis Drugs market is segmented on the basis of:
Types
Riluzole, Edaravone (Radicava), CoQ10, Butylphthalide, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Mitsubishi Tanabe Pharma
- Mylan
- Apotex
- Glemark Generics
- Sun Pharma
- Covis Pharma
- Lunan Pharma
- CSPC Pharmaceutical
- Ascend Laboratories
- EISAI
Highlights of The Amyotrophic Lateral Sclerosis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Riluzole
- Edaravone (Radicava)
- CoQ10
- Butylphthalide
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Amyotrophic Lateral Sclerosis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for ALS, but there are treatments available to help people live longer and improve their quality of life. Drugs used to treat ALS include riluzole (Rilutek), etanercept (Enbrel), and natalizumab (Tysabri). These drugs work by slowing the progression of the disease or by stopping it in its tracks.
Some of the key players operating in the amyotrophic lateral sclerosis drugs market are Sanofi, Mitsubishi Tanabe Pharma, Mylan, Apotex, Glemark Generics, Sun Pharma, Covis Pharma, Lunan Pharma, CSPC Pharmaceutical, Ascend Laboratories, EISAI.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Amyotrophic Lateral Sclerosis Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Amyotrophic Lateral Sclerosis Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Amyotrophic Lateral Sclerosis Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Amyotrophic Lateral Sclerosis Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Amyotrophic Lateral Sclerosis Drugs Market Size & Forecast, 2018-2028 4.5.1 Amyotrophic Lateral Sclerosis Drugs Market Size and Y-o-Y Growth 4.5.2 Amyotrophic Lateral Sclerosis Drugs Market Absolute $ Opportunity
Chapter 5 Global Amyotrophic Lateral Sclerosis Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Type
5.2.1 Riluzole
5.2.2 Edaravone (Radicava)
5.2.3 CoQ10
5.2.4 Butylphthalide
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Amyotrophic Lateral Sclerosis Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Amyotrophic Lateral Sclerosis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Amyotrophic Lateral Sclerosis Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Type
9.6.1 Riluzole
9.6.2 Edaravone (Radicava)
9.6.3 CoQ10
9.6.4 Butylphthalide
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Amyotrophic Lateral Sclerosis Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Type
10.6.1 Riluzole
10.6.2 Edaravone (Radicava)
10.6.3 CoQ10
10.6.4 Butylphthalide
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Amyotrophic Lateral Sclerosis Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Type
11.6.1 Riluzole
11.6.2 Edaravone (Radicava)
11.6.3 CoQ10
11.6.4 Butylphthalide
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Amyotrophic Lateral Sclerosis Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Type
12.6.1 Riluzole
12.6.2 Edaravone (Radicava)
12.6.3 CoQ10
12.6.4 Butylphthalide
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Amyotrophic Lateral Sclerosis Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Type
13.6.1 Riluzole
13.6.2 Edaravone (Radicava)
13.6.3 CoQ10
13.6.4 Butylphthalide
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Amyotrophic Lateral Sclerosis Drugs Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Amyotrophic Lateral Sclerosis Drugs Market: Competitive Dashboard
14.2 Global Amyotrophic Lateral Sclerosis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Mitsubishi Tanabe Pharma
14.3.3 Mylan
14.3.4 Apotex
14.3.5 Glemark Generics
14.3.6 Sun Pharma
14.3.7 Covis Pharma
14.3.8 Lunan Pharma
14.3.9 CSPC Pharmaceutical
14.3.10 Ascend Laboratories
14.3.11 EISAI